随机临床试验:米尔塔扎在功能性消化不良患者中的作用
Lina Cao1, Gaozhong Li2, Jingmei Cao2
1Center of Health Management, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Therapeutic advances in gastroenterology
|January 6, 2025
概括
米尔塔萨平显著改善了对传统治疗无反应的患者的功能性消化不良 (FD) 症状,生活质量和体重. 这项研究表明,米尔塔扎平是有效管理FD的潜在治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 功能性消化不良 (FD) 是一种普遍存在的胃肠道疾病,治疗疗效有限.
- 目前针对FD的治疗方法仅对一小部分患者提供好处.
- 对于FD,米尔塔扎的治疗潜力仍然不完全理解.
研究的目的:
- 为了评估米尔塔扎在功能性消化不良患者的疗效和安全性.
- 评估米尔塔扎对FD症状,生活质量和胃肠道特异性焦虑的影响.
主要方法:
- 一项前性随机临床试验,涉及120名FD患者,传统治疗结果不佳.
- 患者被随机分为两个组:米尔塔扎 (15毫克每天) 加上传统药物,或单独使用传统药物.
- 干预持续了8周,评估了症状,生活质量,焦虑和体重.
主要成果:
- 米尔塔萨平显著降低了腹症状严重程度 (p < 0.001) 和改善了生活质量 (p < 0.001).
- 接受米尔塔扎的患者经历了显著的体重增加和内脏敏感性降低.
- 没有详细说明任何特定的不良反应,但评估了安全性.
结论:
- 米尔塔扎在改善FD患者的整体消化不良症状,生活质量和体重方面表现出显著的疗效.
- 该药物还有效地减少了胃肠道特异性焦虑.
- 米尔塔扎对于治疗功能性消化不良的临床医生来说是一个有前途的治疗选择.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
170
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
170
Antidepressant Drugs: MAOIs and Other Agents
157
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
157
Gastroesophageal Reflux Disease II: Clinical Features and Management
31
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
31
Drugs for Treatment of Diarrhea-Predominant IBS
116
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
116
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
184
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
184
Drugs for Treatment of Constipation-Predominant IBS
108
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
108


